ETH-155008

N/A

Report date: 2023/11/14 11:52:41
NME

Base Information

Drug NameETH-155008
Drug Alias NameETH-155008
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase pim-3 inhibitorsCyclin-dependent kinase 6 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors +[4] 
TargetsSerine/threonine-protein kinase pim-3Cyclin-dependent kinase 6Cyclin-dependent kinase 4 +[4] 
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Promyelocytic, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYunnan Shengke Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShengke Pharmaceutical (Jiangsu) Co LtdYunnan Shengke Pharmaceutical Co Ltd
Inactive CompaniesShengke Pharmaceuticals Pty Ltd
Active IndicationsLymphoma, Non-HodgkinLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute +[4] 
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A